The New England Journal of Medicine
30 FOLLOWERS
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles and editorial opinions on a wide variety of topics of importance to biomedical science and clinical practice.
The New England Journal of Medicine
1M ago
In 67 U.S. communities with a high death rate from opioid overdoses, an intervention to increase the use of evidence-based practices did not result in lower death rates ..read more
The New England Journal of Medicine
1M ago
In this trial, a liberal transfusion strategy did not reduce the risk of an unfavorable neurologic outcome at 6 months in patients with moderate or severe traumatic brain injury and anemia ..read more
The New England Journal of Medicine
1M ago
In this randomized trial involving patients undergoing invasive ventilation, pantoprazole decreased the risk of upper gastrointestinal bleeding as compared with placebo but did not affect mortality ..read more
The New England Journal of Medicine
1M ago
In a randomized trial involving critically ill adults undergoing tracheal intubation, the incidence of hypoxemia was lower with preoxygenation with noninvasive ventilation than with an oxygen mask ..read more
The New England Journal of Medicine
1M ago
In patients with large-vessel ischemic stroke and no access to thrombectomy, tenecteplase given within 4.5 to 24 hours resulted in less disability at 90 days than standard care but also a higher risk of intracranial hemorrhage ..read more
The New England Journal of Medicine
1M ago
In this trial from China involving 1412 patients with acute ischemic stroke presenting within 4.5 hours, the percentage who had an excellent functional outcome at 90 days was 79.5% with reteplase and 70.4% with alteplase ..read more
The New England Journal of Medicine
1M ago
Weekly administration of an anti-CD38 antibody induced elevated platelet counts in 21 of 22 patients with refractory ITP. The main adverse events were infusion reactions ..read more
The New England Journal of Medicine
1M ago
Among patients with relapsed myeloma, median progression-free survival was approximately 3 years with a regimen including belantamab mafodotin, as compared with 13 months with a regimen including an anti-CD38 antibody ..read more
The New England Journal of Medicine
1M ago
In adults with congenital adrenal hyperplasia, crinecerfont, a corticotropin-releasing factor type 1 receptor antagonist, lowered the mean glucocorticoid dose and decreased the mean androstenedione level ..read more
The New England Journal of Medicine
1M ago
Neoadjuvant nivolumab plus ipilimumab results in a substantial pathological response in most patients with mismatch repair–deficient colon cancer and appears to be safe ..read more